HIF1A and cancer: Over the years, its potential as an anticancer therapyhas been investigated.17−19 There are several clinical trials running to assessthe ability of digoxin as a treatment modality for cancer.20−29 Zhang et al. reported that digoxin potently inhibited HIF1-αtranslation and reduced tumor volume.18 Digoxin further inhibited angiogenesis and tumor volume effectivelyin various cancer types.30−32 The effectiveness of digoxinin combination with chemotherapies such as doxorubicin,33 adriamycin,32 andgemcitabine34 have been already investigated.